ABBV 3Q21 Mavyret sales=$426M, -3% QoQ: https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2021-financial-results.htm The $426M consisted of $183M US and $243M ex-US. HCV new-patient starts, particularly in the US, are not (yet) back to pre-pandemic levels.